drugset / Trial / NCT01319240

Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects

NCT01319240

Phase 1 Completed 24 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to compare the bioavailability of insulin degludec and liraglutide, when administered either combined or as separate administrations.

Timeline

Start
2011-03
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Liraglutide Peptide Subcutaneous
Comparator insulin degludec Protein / enzyme biologic Subcutaneous

Indications